Phase I

2026 Oncology Drug Development Planning Realities

As we kickoff 2026, here are the operational…
Read Article

How to Avoid Missing Patient Enrollment Targets in Your First Oncology Study

It’s common for sponsors to miss their patient…
Read Article

Tips for Bringing Your First Oncology Drug into the Clinic in the United States

While cancer is a global health challenge, the…
Read Article

Preparing for Your Phase I Oncology Study

The phase 1 study is the gateway between…
Read Article

Case Study: Rapid Phase I Study Start-Up and Conduct

A European client contracted with Medelis to conduct…
Read Article

Adaptive Trial Design for Phase I, Phase II

Adaptive trial design is a hot issue in…
Read Article

Medelis co-founder Daniel Von Hoff receives prestigious ASCO scientific honor

We are pleased to share the news that…
Read Article

“Context of vulnerability” and its role in targeted drug development

Renowned cancer researcher Dr. Daniel Von Hoff and…
Read Article

The “Lost Opportunity” in Phase I Oncology Trials

Cancer drug developers traditionally use the phase I…
Read Article